Home » myeloid » Recent Articles:

ARIAD Receives Orphan Drug Designations For Its Investigational Pan BCR-ABL Inhibitor, AP24534, In Chronic Myeloid Leukemia

March 3, 2010 Health News No Comments

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S., the orphan designation of AP24534 is for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and in the E.U., its orphan designation is for CML and acute lymphoblastic leukemia…

Go to Source… Continue reading

Sunesis Poised For Phase 3 Trial Of Voreloxin In Acute Myeloid Leukemia After Completing Formal End-of-Phase 2 Meetings With FDA

February 26, 2010 Health News No Comments

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) related to its lead compound, voreloxin, in acute myeloid leukemia (AML). Sunesis has received feedback and guidance from the FDA in response to proposed plans for further development of voreloxin in the treatment of AML. Based on the development clarity achieved as a result of these meetings, Sunesis intends to proceed with its plan to conduct a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial…

Go to Source… Continue reading

Mathematical Model Gives New Hope To Chronic Myeloid Leukaemia Patients

February 23, 2010 Health News No Comments

Doctors can now understand better chronic myeloid leukaemia (CML), including how it responds to therapy, thanks to a new mathematical model for the disease, developed by scientists in Portugal, Belgium and the United States. The work, to be published in the June edition of the journal Haematologica, also reveals that current therapies which are not believed to cure CML with the right protocol can actually get rid of the disease, and provides guidelines on how to do that. CML although rare, because of effective life-extending therapies, is now one of the most common leukaemias in the world…

Go to Source… Continue reading

Novartis Drug Tasigna® Receives FDA Priority Review For Newly Diagnosed Patients With Early-stage Chronic Myeloid Leukemia

February 20, 2010 Health News No Comments

Novartis announced that Tasigna® (nilotinib) has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. FDA priority review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists. This status accelerates the standard review time from 10 to six months…

Go to Source… Continue reading

Novartis Drug Tasigna(R) Receives FDA Priority Review For Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia

February 20, 2010 Health News No Comments

Novartis announced that Tasigna® (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. FDA priority review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists. This status accelerates the standard review time from 10 to six months…

Go to Source… Continue reading

Karolinska Development: EMEA Recommends Orphan Drug Designation For Acute Myeloid Leukemia Treatment

February 19, 2010 Health News No Comments

The European Medicines Agency (EMEA) recommends orphan drug status for Aprea’s treatment of acute myeloid leukemia (AML). The treatment is currently undergoing a Phase I clinical study and a final decision from the European Commission regarding status is expected in a few weeks. Aprea is part of the Karolinska Development portfolio. “Aprea is developing a new class of anticancer drugs for the treatment of acute myelogenous leukemia, the most common acute leukemia affecting adults which is currently lacking efficient treatment…

Go to Source… Continue reading

NICE Appraisal Of Dasatinib And Nilotinib For Chronic Myeloid Leukaemia

January 6, 2010 Health News No Comments

The National Institute for Health and Clinical Excellence (NICE) is currently appraising the use of dasatinib (made by Bristol Myers-Squibb) and nilotinib (Novartis) for chronic myeloid leukaemia in patients whose treatment with imatinib has failed due to resistance and/or intolerance. As with all NICE appraisals, an independent committee of experts and lay people considered evidence presented by the manufacturers of the medicines being appraised…

Go to Source… Continue reading

Novartis Tasigna® Trial Shows Superior Results To Glivec® In Patients With Early-stage Chronic Myeloid Leukemia

December 12, 2009 Health News No Comments

In a large Phase III clinical trial, Tasigna® (nilotinib) demonstrated greater efficacy over Glivec® (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase[1]…

Go to Source… Continue reading

Ambit Biosciences Initiates First Phase 2 Clinical Trial Of AC220 In Acute Myeloid Leukemia

December 12, 2009 Health News No Comments

Ambit Biosciences Corporation announced the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML). AC220 is a novel, orally available, potent and highly selective small molecule that was specifically designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ACE study is designed to be a pivotal trial that could potentially support a United States regulatory filing for AC220 to address a targeted AML patient population with the internal tandem duplication (ITD) activating… Continue reading

Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results To Glivec(R) (imatinib) In Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia

December 9, 2009 Health News No Comments

In a large clinical trial, nilotinib demonstrated greater efficacy over the current gold standard treatment, imatinib, in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase.(1) In the first head-to-head study of these two oral treatments as initial therapy for this life-threatening leukaemia, nilotinib demonstrated statistically significant improvement over imatinib in key measures of effectiveness used in the trial…

Go to Source… Continue reading

ADS:

Featured Content:

FDA Orders 2 Companies To Stop Marketing Unapproved Nitroglycerin Tablets

March 18, 2010

The U.S. Food and Drug Administration today ordered Glenmark Generics of Mahwah, N.J., and Konec Inc. of Tucson, Ariz., to stop marketing unapproved nitroglycerin tablets. The tablets are placed under the tongue to relieve chest pain or to stop a heart attack and are marketed in 0.3 mg, 0.4 mg, and 0.6 mg dosages. The FDA does not anticipate a supply problem for these products. Pfizer Inc. markets FDA-approved sublingual nitroglycerin tablets in the same strengths and is able to supply the market with approved products…

Go to Source… Continue reading

RCN Union Learning Representatives Host Motivational Day For Health Care Staff, Wales

March 18, 2010

The Royal College of Nursing in Wales in partnership with a local nurse from Abertawe Bro Morganwg Local Health Board has organised an event for health care staff working within the NHS and independent sector at the Aberavon Hotel, Port Talbot on Monday, 1 March, 2010. This event was sponsored by the Welsh Union Learning Fund. The event is a motivational seminar for health care staff and in the spirit of partnership, invitations have been offered to other local union members. A selection of inspirational speakers will feature throughout the day…

Go to Source… Continue reading

Improved liquid chromatography-tandem mass spectrometry method in clinical utility for the diagnosis of Cushing’s syndrome.

March 18, 2010

Authors: Fong BM, Tam S, Leung KS
Determination of urinary free cortisol is one of the first lines in screening for the diagnosis of Cushing’s syndrome where its measurement is mostly done by immunoassay. Although easy to perform, immunoassays suffer from the problem of assay interferences and are unable to measure cortisone levels. To enhance such techniques for clinical diagnosis, an improved liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed for the simultaneous determination of urinary free cortisol and cortisone. The leftover urine samples from immunoassay were collected and subjected to facile solid-phase extraction cleanup. In the analysis of 130… Continue reading

RCN In Wales Supports Plans To Help Veterans

March 18, 2010

Royal College of Nursing Applauds Welsh Assembly Government’s Plan to Help Military Veterans Tina Donnelly, Director of the Royal College of Nursing in Wales, said: “The Royal College of Nursing in Wales is pleased that the Welsh Assembly Government is allocating additional funding to support our military veterans. Our military veterans have demonstrated unmatched dedication to public service and our government should be able to help them out in their time of need…

Go to Source… Continue reading

Skin Cancer Epidemic Underrecognized, US Study

March 18, 2010

US researchers who analysed over a decade’s worth of statistics on non-melanoma skin cancers in the US (the country’s most common form of cancer) found they have been rising steadily every year, and concluded that their findings reveal the “most complete evaluation to date of the underrecognized epidemic of skin cancer in the United States”. A paper on the study, which was conducted by lead author Dr Howard W. Rogers, a dermatologist from Norwich, Connecticut, and colleagues, appears online in the March issue of the journal Archives of Dermatology…

Go to Source… Continue reading

Nurses Call For Improvements To Dementia Care, UK

March 18, 2010

Commenting on the Public Accounts Committee report Improving dementia services in England – an interim report, Janet Davies, Executive Director of Nursing and Service Delivery at the Royal College of Nursing (RCN), said: “It is deeply concerning that dementia care is still not being dealt with as a priority. Training and education for healthcare staff working in all settings is absolutely vital if care for dementia patients is to improve. Greater investment is also needed for specialist dementia nurses, who provide invaluable support for dementia patients, their carers and families…

Go to Source… Continue reading

Obama: Health Bill Debate Too Focused On ‘Washington Process’

March 18, 2010

Fox News’ Bret Baier interviewed the president this afternoon: “President Obama is not worried about the ‘procedural’ debate over whether House Democratic leaders should go ahead with a plan to approve health care reform without a traditional vote … ’What I can tell you is that the vote that’s taken in the House will be a vote for health care reform.’” Fox has video of the interview (3/17).

Reuters: “Party leaders are considering using a complicated process to avoid a direct vote on the Senate-passed bill, which is unpopular with House Democrats. Instead, they would declare the Senate bill passed… Continue reading

Is Varmus Headed to the National Cancer Institute?

March 18, 2010

Ever since Harold Varmus’s January public letter stating he asked Memorial Sloan-Kettering Cancer Center’s board to start looking for his successor as president, people have been wondering what the Nobel laureate is going to do next.
Now there may be an answer: Varmus is expected to be nominated by the White House very soon to head the National Cancer Institute, according to The Cancer Letter, a publication read by many in the cancer field.
There hasn’t been any official confirmation of the news. Rumors about his imminent appointment have circulated before but they were shot down earlier this month by Varmus… Continue reading

Recent Comments:

  • symptoms of dementia: What's the difference between dementia and Alzheimers? what is the difference? I think my father may be suffering one of these? does anyone know the w...
  • rani: good blog thank 4 the info...
  • JourneyHome: McCarran-Ferguson was originally designed to empower both the federal government and the individual states so that they could act to prevent insurance...
  • Hydro Closet: Hi, I thought I would say you have a wonderful site and rich content. I bookmarked your site and have it in my reader now...looking forward to future ...
  • Allan Ono: Getting more usage from drugs already approved by the FDA for new indications seems like a very good way to expand treatment options without the hyper...